$7.02
2.48% yesterday
Nasdaq, Dec 23, 10:00 pm CET
ISIN
US56400P7069
Symbol
MNKD
Sector
Industry

MannKind Corporation Stock price

$7.02
+0.30 4.46% 1M
+1.59 29.28% 6M
+3.38 92.86% YTD
+3.42 95.00% 1Y
+2.56 57.40% 3Y
+5.71 435.88% 5Y
-20.48 74.47% 10Y
Nasdaq, Closing price Mon, Dec 23 2024
+0.17 2.48%
ISIN
US56400P7069
Symbol
MNKD
Sector
Industry

Key metrics

Market capitalization $1.94b
Enterprise Value $2.03b
P/E (TTM) P/E ratio 99.86
EV/FCF (TTM) EV/FCF 71.19
EV/Sales (TTM) EV/Sales 7.60
P/S ratio (TTM) P/S ratio 7.25
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 51.35%
Revenue (TTM) Revenue $267.20m
EBIT (operating result TTM) EBIT $57.25m
Free Cash Flow (TTM) Free Cash Flow $28.54m
Cash position $251.59m
EPS (TTM) EPS $0.07
P/E forward 67.94
P/S forward 6.84
EV/Sales forward 7.18
Short interest 15.31%
Show more

Is MannKind Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.

MannKind Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a MannKind Corporation forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a MannKind Corporation forecast:

Buy
100%

Financial data from MannKind Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
267 267
51% 51%
100%
- Direct Costs 75 75
23% 23%
28%
192 192
66% 66%
72%
- Selling and Administrative Expenses 83 83
8% 8%
31%
- Research and Development Expense 44 44
51% 51%
16%
65 65
1,827% 1,827%
24%
- Depreciation and Amortization 7.86 7.86
41% 41%
3%
EBIT (Operating Income) EBIT 57 57
712% 712%
21%
Net Profit 22 22
169% 169%
8%

In millions USD.

Don't miss a Thing! We will send you all news about MannKind Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MannKind Corporation Stock News

Neutral
Seeking Alpha
7 days ago
MannKind Corporation is a biopharmaceutical company focused on inhaled therapies for endocrine and orphan lung diseases. MNKD's revenue growth is driven by Tyvaso DPI royalties and Afrezza expansion, with pediatric trials targeting a significant underserved market. MNKD's pipeline includes MNKD-101 for nontuberculous mycobacterial lung disease and MNKD-201 for idiopathic pulmonary fibrosis, wit...
Neutral
GlobeNewsWire
8 days ago
Company plans to meet with FDA regarding potential sNDA submission in 1H 2025 Call planned today at 8:30 a.m. (ET) to discuss company's diabetes program progression DANBURY, Conn.
Neutral
GlobeNewsWire
13 days ago
India has the 2 nd highest burden of diabetes worldwide CDSCO decision follows existing approvals in the U.S.A. and Brazil MannKind expects to ship product for Cipla Ltd.
More MannKind Corporation News

Company Profile

MannKind Corp. is a biopharmaceutical company. It focuses on the discovery, development and, commercialization of therapeutic products for diseases, such as diabetes and cancer. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Westlake Village, CA.

Head office United States
CEO Michael Castagna
Employees 414
Founded 1991
Website www.mannkindcorp.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today